City and hospital collaboration to find early liver fibrosis in the Grenoble area
City-Hospital Collaboration for Early Detection of Liver Fibrosis in Primary Care: A Secondary Prevention Project in the Grenoble Health Area
This project tests using a simple FIB‑4 blood score followed by a FibroScan to find early liver fibrosis in adults referred by their primary-care doctor in the Grenoble area.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 2 sites (Grenoble and 1 other locations) |
| Trial ID | NCT07031089 on ClinicalTrials.gov |
What this trial studies
This observational secondary-prevention project follows adults referred by primary-care providers for liver fibrosis screening using the FIB‑4 score and transient elastography (FibroScan). Eligible participants are adults who had FIB‑4 > 1.3 and underwent FibroScan at CHU Grenoble-Alpes or CPTS-SEG between January 2023 and January 2026, with FibroScan results ≥ 8 kPa. The work documents how often advanced fibrosis is detected in this real-world primary-care pathway and how patients are routed to hospital care. The protocol is non-interventional and uses routine clinical data to measure detection rates and referral patterns.
Who should consider this trial
Good fit: Adults aged 18 or older who were referred by a general practitioner or authorized primary-care provider, had FIB‑4 > 1.3, and underwent FibroScan at CHU Grenoble-Alpes or CPTS-SEG between January 2023 and January 2026 with a result ≥ 8 kPa are the intended participants.
Not a fit: People already known to have chronic liver disease and already under specialist follow-up, those with FibroScan < 8 kPa, or those legally unable to consent (under guardianship or deprived of liberty) are unlikely to benefit from this screening project.
Why it matters
Potential benefit: If successful, the program could catch advanced fibrosis earlier so patients can get timely follow-up and treatment to reduce progression to cirrhosis and liver cancer.
How similar studies have performed: Previous programs using FIB‑4 followed by transient elastography in primary care have successfully identified patients with advanced fibrosis, though implementation and follow-up vary by region.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 years or older * Having undergone a Fibroscan® at the CHU de Grenoble-Alpes or CPTS-SEG, requested by a primary care practitioner (general practitioner, non-hospital diabetologist, Asalée nurse), as part of the screening recommendations for liver fibrosis in the case of a FIB4 score \> 1.3 * With a result ≥ 8kPa * Between January 2023 and January 2026 Exclusion Criteria: * Patients who have expressed their opposition to participating in the study * Patients under guardianship or deprived of liberty * Patients with a known chronic liver disease who are being monitored at the time of the Fibroscan® procedure
Where this trial is running
Grenoble and 1 other locations
- Communauté Professionnelle Territoriale de Santé Sud Est Grenoblois — Grenoble, France (Not_yet_recruiting)
- Grenoble Alpes University Hospital — Grenoble, France (Recruiting)
Study contacts
- Study coordinator: Anna Borowik, PhD
- Email: aborowik@chu-grenoble.fr
- Phone: +33476769314
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.